DIA names new managing director for China
This article was originally published in Scrip
Life Sciences association, the DIA, has named Dr Haijun Dong managing director in China. Dr Dong was previously chief executive officer of Lilly China Research and Development, a subsidiary of Eli Lilly, and was president and CEO of IMPACT Therapeutics. Furthermore, Dr Dong has in the past worked for Swiss big pharma Roche in China and the US. He succeeds Dr Jane Cai, who is retiring from the role of MD for DIA China.